The Latest Breaking News from AbbVie

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy.  AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Low-risk dividend stocks are coveted. Better yet, here are quality CAN-SLIM stocks that pay at least double the S&P 500 index's yield.

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and inflammatory diseases. Cugene's lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells for autoimmune…

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy.  A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Led with a more-than $3 billion bet on Apple, the best mutual funds continue to invest heavily during this market correction.

Most mutual funds have losses this year amid the market's sell-off. But JPMorgan Large Cap Value Fund is in positive territory. Here's why.

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

The stock market sank to session lows in afternoon trading Friday as index losses topped 2%. The S&P 500 plunged 2.1% and undercut Thursday's lows, essentially wiping out almost all of that day's 2.5% rally. The Nasdaq composite slid 2.4%, though it is holding above Thursday's low. The Dow Jones…